Science|Business reported that the EU and US have reached an agreement in principle on facilitating data flows across the Atlantic. Steady data sharing has been hampered since the EU’s Court of Justice struck down the old rules due to concerns about US government surveillance in July 2020.

This will also have impact for the healthcare sector as the data in question include research data shared by companies that take part in the EU framework research programmes, such as the results of clinical trials required to get approval of new drugs. For the healthcare sector that relies on huge data flows globally to sustain its work, the agreement in principle promises legal certainty. Brendan Barnes, director for IP and data protection at the European Federation of Pharmaceutical Industries and Associations, says the initial reaction to the deal has been positive although it is too early to draw conclusions on its impact.

Learn more: